



HAL
open science

Broad-Based SARS-CoV-2 Testing Program for Healthcare Workers in a Primary Care Hospital in France

Julie Chas, Marine Nadal, Martin Siguier, Anne Fajac, Michel Denis,
Laurence Morand-Joubert, Gilles Pialoux

► **To cite this version:**

Julie Chas, Marine Nadal, Martin Siguier, Anne Fajac, Michel Denis, et al.. Broad-Based SARS-CoV-2 Testing Program for Healthcare Workers in a Primary Care Hospital in France. *Infectious Diseases Now*, 2021, 51 (6), pp.556–559. 10.1016/j.idnow.2020.11.016 . hal-03793444

HAL Id: hal-03793444

<https://hal.sorbonne-universite.fr/hal-03793444v1>

Submitted on 16 Oct 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Title page

Broad-based SARS-CoV-2 Testing Program for Healthcare Workers in a Primary Care Hospital In France.

Julie Chas, MD, Marine Nadal, MD, Martin Siguier, MD, Anne Fajac, MD, PhD, Michel Denis, MD, Laurence Morand-Joubert, MD, PhD, Gilles Pialoux, MD, PhD.

Author affiliations : Infectious Diseases department, Tenon Hospital, AP-HP, Paris, France (Chas, Nadal, Siguier, Pialoux); Pathology department, Tenon Hospital, AP-HP, Paris, France (Fajac); Hygiene Unit, Tenon Hospital, AP-HP, Paris, France (Denis); INSERM-Sorbonne Universités UPMC Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Department of virology, AP-HP, Paris, France (Morand-Joubert).

Corresponding Author: Gilles. Pialoux MD, PhD, Infectious Diseases department, Tenon Hospital, AP-HP, and Sorbonne Université Paris, France (gilles.pialoux@aphp.fr)

Abstract (72 words)

A broad-based SARS-CoV-2 testing program for all symptomatic healthcare workers (HCWs) was implemented in Tenon hospital, Paris, France. From February 26 to April 22, 2020, 701 symptomatic HCWs were screened, of whom 247 (35.2%) tested positive for SARS-Cov-2. Myalgia, fever, anosmia and ageusia were associated with RT-PCR positivity. Testing of HCWs is an essential step toward control of the epidemic. Further studies could establish clinical algorithms for SARS-CoV-2 diagnosis to compensate for RT-PCR test and chest CT limits or unavailability.

Keywords : Sars-CoV-2, testing, health care workers, hospital-acquired infection Sars-CoV-2

Manuscript (979 words)

Introduction

The first three European cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were reported in France on January 24, 2020 and the first death on February 15¹. Between February 26 and April 22, 2020, 595 patients were hospitalized in our establishment for SARS-CoV-2 infections, including 57 cases in intensive care unit and 113 deaths. We observed 247 cases of Healthcare worker (HCW) infections. HCWs are defined in the broadest sense as any staff working in the hospital, including cleaning or technical support, who might be exposed directly or indirectly to SARS-CoV-2, and are consequently at higher risk of contracting SARS-CoV-2 infection. Personal protective equipment (PPE) is advisable to ensure healthcare system functioning². Based on the guidelines established by the French Infectious Diseases Society (SPILF-COREB)³, mandatory precautions for the management of SARS-CoV-2 patients include droplets and contact precautions. On March 16, the day before the French national lockdown, these measures were extended to all hospital personnel. In order to prepare post-lockdown and to minimize a possible second

epidemic wave, we felt it was important: i) to study whether the preventive measures adopted to protect HCWs were effective; ii) to identify symptoms predictive of SARS-CoV-2 infection, the objective being to detect it clinically: (a) in a specific context of shortage of masks and RT-PCR screening tests in France⁴, (b) in the context of possible false negatives with RT-PCR tests⁵ and (c) with the expectation of better performing tests (PCR and antigens) and chest CT with very good positive predictive value⁶ but limited access.

Method

Between February 26 and April 22, 2020, in our hospital, broad-based screening for SARS-CoV-2 was implemented for all symptomatic HCWs exhibiting fever, respiratory symptoms (dyspnea, cough or sore throat) and/or any other clinical symptoms (e.g. myalgia, headache). The diagnosis of SARS-CoV-2 was performed by RT-PCR on a nasopharyngeal swab. During screening, age, occupation, comorbidities, temperature, oxygen saturation, and symptom history were recorded. On April 23, 2020, a telephone interview was conducted with HCWs positive for SARS-CoV-2 to collect information on possible modes of transmission and clinical outcomes. The questions regarding modes of contamination were: Do you think you were infected i) in hospital with a patient positive for SARS-Cov-2; ii) in hospital with a colleague positive for SARS-Cov-2; iii) in the community, through family contacts, during transport, or during festive outings prior to the lockdown period? Differences in symptom frequency between positive and negative HCWs were evaluated using the Chi2 and Fisher tests. The symptoms were summarized in a standardized questionnaire. All data were collected prospectively in the DIAMM-G computer database (Micro6 Nancy, France) except for suspected mode of contamination. The study was approved by the French data protection authority (CNIL: N°2217729). The statistical analyses were conducted on STATA software,

version 14.0 (Statacorp, Texas, United States). A downward stepwise multivariate logistic regression including significant variables with p value < 0.20 in univariate analyses was carried out. A correlation test on the different variables was performed to ensure their independence.

Results

Out of the 3030 HCWs working at our hospital, 701 (23.1%) reported symptoms between February 26 and April 22. All of them were screened and 247/741 (35.2%) tested positive for SARS-CoV-2, representing a prevalence of 247/3030 (8.1%). Among those having reported symptoms and tested positive for SARS-CoV-2 ($n=247$), median age was 36 years (IQR, 18-64), 171 (69.2%) were female and 209 (84.6%) carried out direct patient care; the remainder included administrative assistants, environmental service employees, and maintenance workers. Occupations strongly positively associated with SARS-CoV-2 positivity were maintenance workers (OR=3.8; 95% confidence interval (CI):1.3-11.2) and caregivers (OR=1.8; 95% confidence interval (CI):1.2-2.7). Among the 201/247 (46 missing answers) HCWs contacted by phone, 178 (88.5%) retrospectively reported on their hospital-acquired infection. Clinically speaking, 194 (96.5%) never needed hospitalization, 4 (2%) went to the emergency room, 3 (1.5%) were hospitalized. No intensive care hospitalizations or deaths were reported.

In univariate analysis, myalgia, fever, anosmia and ageusia (general non-respiratory symptoms) were positively associated with test-positivity. The two symptoms most strongly associated with SARS-CoV-2 positivity were anosmia (OR=6.3; 95% confidence interval (CI):3.8-10.4), reported by 25.1% of test-positives, and ageusia (OR=4.1; 95% confidence interval (CI): 2.5-6.9) reported by 19.4% of test-positives. On the other hand, diarrhea and

respiratory symptoms (dyspnea, sore throat and coryza) were negatively associated with the disease (Table). The model included all variables except ageusia. In multivariate analysis, SARS-CoV-2 infection was significantly positively associated with anosmia (OR=9.5; 95% confidence interval (CI): 5.3-17.1), myalgia (OR=1.8; 95% confidence interval (CI): 1.3-2.6) and fever (OR=1.7; 95% confidence interval (CI): 1.2-2.5). SARS-CoV-2 infection was significantly negatively associated with coryza (OR=0.6; 95% confidence interval (CI): 0.4-0.8), diarrhea (OR=0.4; 95% confidence interval (CI): 0.2-0.8), sore throat (OR=0.3; 95% confidence interval (CI): 0.2-0.6) and dyspnea (OR=0.3; 95% confidence interval (CI): 0.2-0.5). The curve of the number of HCWs tested positive daily for SARS-CoV-2 is congruent with the curve corresponding to patients in the hospital (Figure). It began to decline about ten days after masks began to be worn continuously by HCWs and the French lockdown was put in place, whereas the total number of patients hospitalized for SARS-CoV-2 in all French hospitals continued to rapidly increase before leveling off.

Discussion

Contrary to what was described at the outset of the epidemic^{7,8}, the symptoms significantly associated with positive SARS-CoV-2 infection are generally **non-respiratory**. It also bears mentioning that in our study, the incidence rate among HCWs was probably underestimated because at first, only HCWs with fever and respiratory signs were encouraged to come for testing; only later was the clinical picture widened to include other possible signs of SARS-CoV-2 infection.

While reported a steep decrease in the curve corresponding to the number of HCWs tested positive for SARS-CoV-2 on a day-to-day basis, we were unable to determine whether or not it was closely associated with the PPE adopted for the protection of HCWs in an unconfined

population. The high level of hospital-acquired infection reported in our study is probably overestimated by self-reporting in the absence of precise contact screening with risk stratification inside and outside the hospital. For example, the possibility that hospital-acquired contamination may have been overestimated so as to have it recognized as an occupational disease cannot be ruled out. In a retrospective analysis of documented cases, a majority of hospital-acquired infections occurred prior to systematic testing of patients and the general adoption of protective measures¹.

Even though the numbers are small, our study highlights an increasing risk among maintenance workers (OR 3.8 [1.3-11.2 95% CI; p:0.014]). The cleaning staff included in the "maintenance workers" group are not part of the hospital staff insofar they are often employed by a private company. While some of them were included in our study when they showed symptoms, the results are not exhaustive of this group. As proof, we have included them more widely in our current serological study (data not shown); out of the first 50 serologies performed in the cleaning agents, 23/50 were negative and 27/50 (54%) were positive, 9 of whom were included in the present RT-PCR study, i.e. 7/10 PCR positive and 2/5 negative, which effectively illustrates the limits of RT-PCR.

More generally, our findings data highlight a group of in-hospital workers who may have been widely contaminated in the social conditions of living and transport during a lockdown period. This is particularly the case at the hospital for cleaning staff, firemen, security guards, kitchen staff... This highly diversified population requires special attention in terms of screening, information and isolation of positive persons in the event of a second wave.. As a means of overcoming RT-PCR and chest CT limits, decision algorithms based on clinical and biological criteria of SARS CoV-2 infection such as those applied in our study could be useful for public health purposes, particularly with regard to a population of highly exposed

paucisymptomatic healthcare workers, and possibly in emerging countries. In numerous countries, large-scale population testing is impossible due to the limited availability and costs of RT-PCR kits and CT-scan. Pre-test probability combining clinical and biological features should be the subject of prospective or retrospective studies with a control group. Lastly, testing of HCWs is an essential step to control this epidemic. The Centers for Disease Control and Prevention⁹ recently provided guidance on the appropriate use of HCW testing, which can be considered in four situations: Testing HCWs with signs or symptoms consistent with COVID-19; Testing asymptomatic HCWs with known or suspected exposure to SARS-CoV-2; Testing asymptomatic HCWs without known or suspected exposure to SARS-CoV-2 for early identification in special settings (e.g., nursing homes); Testing HCWs who have been diagnosed with SARS-CoV-2 infection to determine when they are no longer infectious. Further studies should make it possible to distinguish between community-, home-, and health care–acquired exposures¹⁰.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by Tenon and St Antoine Hospital, AP-HP, Paris.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References

1. Bernard Stoecklin S, Rolland P, Silue Y, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020;25(6). doi: 10.2807/1560-7917.ES.2020.25.6.2000094.
2. Centers for Disease Control and Prevention. Coronavirus disease 2019: Interim U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with Coronavirus Disease 2019 (COVID-19). Updated April 12, 2020. Accessed April 15, 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html>
3. Coignard-Biehler H, Rapp C, Chapplain JM, et al. The French Infectious Diseases Society's Readiness and Response to Epidemic or Biological Risk-The Current Situation Following the Middle East Respiratory Syndrome Coronavirus and Ebola Virus Disease Alerts. *Med Mal Infect.* 2018 Mar;48(2):95-102. doi: 10.1016/j.medmal.2017.10.002.
4. Moatti J-P. The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy. *Lancet Public Health.* 7 avr 2020. doi: 10.1016/S2468-2667(20)30087-6.
5. Li Y, Yao L, Li J, et al. Stability Issues of RT-PCR Testing of SARS-CoV-2 for Hospitalized Patients Clinically Diagnosed With COVID-19. *J Med Virol.* 2020 Mar 26. doi: 10.1002/jmv.25786.
6. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology.* 2020 Feb 19;200432. doi: 10.1148/radiol.2020200432.
7. Huang C, Wang Y, Li X, et al. Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. *Lancet.* 2020 Feb 15. doi: 10.1016/S0140-6736(20)30183-5.
8. Centers for Disease Control and Prevention. Characteristics of Health Care Personnel with COVID-19 — United States, February 12–April 9, 2020. Updated April 14, 2020. Accessed April 17, 2020. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e6.htm>.
9. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing.html>

10 Moscola J, Sembajwe G, Jarrett M, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care

Personnel in the New York City Area. JAMA. 2020 Aug 6. doi: 10.1001/jama.2020.14765.

Figure - Epidemic curve of patients and Health Care Workers with confirmed SARS-CoV-2 Infection - Tenon Hospital, AP-HP, Paris, France




Table 1. Characteristics of Healthcare Workers screened for SARS-CoV-2 Infection (N=701)-Tenon Hospital, AP-HP, Paris, France.

Screening Characteristic	No. (%)		OR (95% CI)	p value
	Positive SARS-CoV-2 PCR test result (N=247)	Negative SARS-CoV-2 PCR test result (N=454)		
Age, median (IQR), y	36 (18-64)	36 (19-67)	1 [0,9-1]	0.943
Sex				
Male	76 (30.8)	109 (24)	0.7 [0.5-1]	0.053
Female	171 (69.2)	345 (76)		
Occupation				
Direct patient care				
Nurse	209 (84.6)	390 (85.9)	0.9 [0.5-1.4]	0.644
Caregiver	68 (27.5)	102 (22.5)	1.3 [0.9-1.9]	0.136
Physician	56 (22.7)	63 (13.9)	1.8 [1.2-2.7]	0.003
Student	44 (17.8)	79 (17.4)	1 [0.7-1.5]	0.891
Other ^a	15 (6.1)	43 (9.5)	0.6 [0.3-1.1]	0.119
Environmental employees	26 (10.5)	103 (22.7)	0.4 [0.2-0.6]	<0.001
Administrative assistants	18 (7.3)	31 (6.8)	1.1 [0.6-1.9]	0.820
Maintenance workers	10 (4)	28 (6.2)	0.6 [0.3-1.3]	0.237
Any comorbidities ^b	10 (4)	5 (1.1)	3.8 [1.3-11.2]	0.014
Days from symptom onset to screening, mean (SD)	46 (18.6)	171 (37.6)	0.4 [0.3-0.5]	<0.001
Symptoms reported				
Cough	3.3 (1-16)	5.8 (1-42)	0.9 (0.9-0.9)	<0.001
Myalgias	134 (54.3)	257 (56.6)	0.9 [0.7-1.2]	0.548
Headache	112 (45.3)	151 (33.3)	1.7 [1.2-2.3]	0.002
Fever	111 (44.9)	184 (40.5)	1.1 [0.8-1.6]	0.398
Coryza	91 (36.8)	105 (23.1)	1.9 [1.4-2.7]	<0.001
Asthenia	79 (32)	192 (42.3)	0.6 [0.5-0.9]	0.008
Anosmia	77 (31.2)	132 (29.1)	1.1 [0.8-1.5]	0.562
Ageusia	62 (25.1)	23 (5.1)	6.3 [3.8-10.4]	<0.001
Chills	48 (19.4)	25 (5.5)	4.1 [2.5-6.9]	<0.001
Dyspnea	40 (16.2)	64 (14.1)	1.2 [0.8-1.8]	0.455
Diarrhea	25 (10.1)	100 (22)	0.4 [0.2-0.6]	<0.001
Sweats	16(6.5)	57 (12.6)	0.5 [0.3-0.9]	0.013
Sore throat	14 (5.7)	19 (4.2)	1.4 [0.7-2.8]	0.376
Nausea/vomiting	14 (5.7)	68 (15)	0.3 [0.2-0.6]	<0.001
Chest pain	14 (5.7)	31 (6.8)	0.8 [0.4-1.6]	0.549
Abdominal pain	9 (3.6)	27 (5.9)	0.6 [0.3-1.3]	0.191
Conjunctivitis	7 (2.8)	20 (4.4)	0.6 [0.3-1.5]	0.306
Anorexia	2 (0.8)	9 (2)	0.4 [0.1-1.9]	0.344
Anorexia	2 (0.8)	5 (1.1)	0.7 [0.1-3.8]	0.100
Telephone Interview Characteristic^c	N=201			
Exposures				

Only patient exposure	69 (34.3)	-
Only colleague exposure	49 (24.4)	-
Only patient and colleague exposure	41 (20.4)	-
Only household/community exposure	19 (9.4)	-
Multiple exposure settings	15 (7.5)	-
Unidentified exposure	8 (4)	-
Outcomes		
Emergency	4 (2)	-
Hospitalization	3 (1.5)	-
Intensive care unit admission	0	-
Death	0	-
^a Physiotherapist, psychologist, dietician, pharmacist, radiological manipulator.	biotherapy and/or immunosuppressive dose corticosteroid therapy; uncontrolled HIV infection or with CD4 <200/mm ³ ; following a solid organ or hematopoietic stem cell transplant; related to a malignant hemopathy being treated), cirrhosis at least stage B of the Child-Pugh classification, morbid obesity (body mass index > 40 kg/m ²), splenectomy, women in the 2nd and 3rd trimester of pregnancy, caregivers aged 70 and over.	
^b Cardiovascular history (complicated hypertension, stroke, coronary artery disease, heart surgery, heart failure stage NYHA III or IV), insulin-dependent diabetes that is unbalanced or with complications, chronic respiratory pathology that may decompensate in viral infection, chronic kidney disease dialysis, treated cancer, congenital or acquired immunosuppression (drug: cancer chemotherapy, immunosuppressive chemotherapy,	^c 46 missing answers (201/247).	

Table 2. Multivariate logistic regression analysis of symptoms reported (455 no cases and 247 cases)

Symptoms reported	P	Odds Ratio	95% CI
Myalgia	0.001	1.833187	[1.279578 - 2.626314]
Fever	0.005	1.728242	[1.179459 - 2.532363]
Coryza	0.003	0.5714433	[0.3952203 - 0.8262416]
Anosmia	0.000	9.530877	[5.310531 - 17.10519]
Dyspnea	0.000	0.3046972	[0.1774645 - 0.5231493]
Diarrhea	0.006	0.4182267	[0.2233374 - 0.7831809]
Sore throat	0.001	0.325374	[0.1703906 - 0.621327]

Logistic model for RésultatsPCR, goodness-of-fit test

```

number of observations =      701
number of covariate patterns =    71
Pearson chi2 (63) =      63.83
Prob > chi2 =      0.4472

```